Monthly Cost Planning for 1.7mg Wegovy vs Mounjaro Treatment
Understanding 1.7mg Wegovy vs Mounjaro Monthly Cost Differences
When comparing 1.7mg Wegovy vs Mounjaro monthly costs, several factors influence your long-term budget planning. Wegovy follows a structured dose escalation protocol, with 1.7mg representing weeks 13–16 before reaching the 2.4mg maintenance dose. Mounjaro utilises a different titration schedule with its dual GIP/GLP-1 receptor agonist mechanism, potentially affecting monthly expenditure patterns. The key consideration is that 1.7mg Wegovy is a temporary stepping stone, making cost comparison most relevant when considering the transition to maintenance dosing.
At EverydayMeds, we recognise that planning your monthly treatment budget requires transparency about both immediate and ongoing costs. The 1.7mg dose period represents a critical juncture where patients often evaluate long-term treatment sustainability. Our pricing structure reflects this journey, with the Elevate Duo bundle specifically designed to bridge the gap between 1.7mg and 2.4mg maintenance therapy. This approach ensures cost predictability during your transition phase.
Detailed Pricing Structure for 1.7mg Wegovy vs Mounjaro Comparison
Wegovy 1.7mg costs £139.99 for the four-week treatment period, representing weeks 13–16 of your dose escalation journey. For customers planning their transition to maintenance, our Elevate Duo bundle combines 1.7mg and 2.4mg pens for £369.99, providing eight weeks of treatment including your first month at maintenance dose. New customers apply code FIRST40 at checkout, whilst returning customers use DOSE25 to maintain optimal pricing. The progression to 2.4mg maintenance incurs £209.99 monthly, equating to approximately £2,520 annually for ongoing treatment.
Mounjaro pricing follows a different structure reflecting its unique titration schedule and dual-agonist formulation. When evaluating 1.7mg Wegovy vs Mounjaro monthly costs, consider that Wegovy's 1.7mg dose is specifically positioned as the penultimate step before maintenance. The storage advantage of Wegovy (6 weeks at room temperature versus Mounjaro's 21 days) may influence practical costs including travel and storage considerations. Both prescription-only medicines are available through our GPhC-registered pharmacy, ensuring clinical oversight and authentic medication supply.
Clinical Evidence Supporting 1.7mg Wegovy vs Mounjaro Cost Effectiveness
The STEP clinical trial programme demonstrated that patients taking Wegovy alongside diet and exercise achieved approximately 15% average weight loss at 68 weeks (Wilding et al., NEJM, 2021). This evidence supports the structured dose escalation including the 1.7mg phase, justifying the monthly cost investment for sustainable weight management outcomes. The clinical data suggests that reaching and maintaining the therapeutic dose provides optimal treatment benefit.
When comparing 1.7mg Wegovy vs Mounjaro from a clinical perspective, both medications have demonstrated efficacy in their respective trial programmes. The investment in either treatment represents a commitment to medically-supervised weight management alongside a reduced-calorie diet and increased physical activity. The monthly cost should be evaluated against potential long-term health benefits and reduced healthcare utilisation costs.
Wegovy Mechanism and Value Proposition for Monthly Investment
Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics natural fullness hormones to reduce appetite and promote satiety after smaller meals. The medication may reduce food cravings by working on brain appetite centres, supporting sustainable dietary changes essential for long-term weight management. The once-weekly injection via FlexTouch pen provides convenience, potentially improving treatment adherence compared to daily medications. The structured dose escalation to 1.7mg ensures optimal tolerance whilst building towards therapeutic maintenance dosing. Understanding this mechanism helps justify the monthly cost as an investment in physiologically-supported appetite regulation rather than short-term intervention.
Streamlined Ordering Process for 1.7mg Wegovy vs Mounjaro Cost Comparison
EverydayMeds facilitates easy comparison and ordering for both treatment options through our three-minute online clinical assessment, designed to gather essential medical information for prescriber review. Our qualified prescribers evaluate your suitability for either Wegovy or Mounjaro within three working days (or 24 hours with express service), ensuring appropriate clinical oversight. Once approved, next-day delivery via cold-chain, temperature-controlled transport maintains medication integrity from our GPhC-registered pharmacy to your door. The transparent pricing structure eliminates hidden costs, allowing accurate monthly budget planning. This efficient process ensures minimal delay between clinical approval and treatment commencement, optimising your weight management journey timing.
Storage Considerations Affecting 1.7mg Wegovy vs Mounjaro Monthly Costs
Wegovy requires refrigeration at 2–8°C before first use but offers superior room temperature stability, remaining viable for six weeks below 30°C once removed from the fridge. This storage advantage over Mounjaro's 21-day room temperature limit may reduce wastage costs and provide greater flexibility for travel or storage interruptions. The FlexTouch pen design ensures consistent dosing accuracy, whilst the structured escalation protocol minimises dose confusion or administration errors. The 1.7mg dose represents the penultimate step in this carefully calibrated journey, making storage reliability crucial for maintaining treatment continuity. Proper storage protects your monthly investment whilst ensuring optimal therapeutic benefit from each injection.
Long-term Budget Planning for 1.7mg Wegovy vs Mounjaro Maintenance Costs
The transition from 1.7mg Wegovy to 2.4mg maintenance represents a pivotal moment in long-term budget planning, with annual maintenance costs approximately £2,520 for ongoing treatment. Our Consistency 2.4mg bundle (two pens for £419.99) provides two-month supply convenience, whilst the Ultimate Stability Trio offers three-month security at £649.99. Understanding that STEP trial extension data showed weight regain of approximately two-thirds within one year of stopping treatment emphasises the importance of sustained therapy budgeting.
When evaluating 1.7mg Wegovy vs Mounjaro for long-term commitment, consider that weight management represents an ongoing health investment rather than short-term intervention. The monthly cost structure at maintenance level provides predictable budgeting, whilst our DOSE25 returning customer discount ensures consistent pricing for loyal patients. Both treatments require indefinite continuation for sustained benefit, making monthly cost sustainability a crucial factor in medication selection and long-term treatment success.
Expert Clinical Support and Value-Added Services
EverydayMeds provides comprehensive support throughout your 1.7mg Wegovy vs Mounjaro decision-making process, with qualified prescribers available to discuss clinical suitability and cost considerations. Our GPhC registration (#9012878) ensures full regulatory compliance and professional oversight throughout your treatment journey. The monthly cost includes not just medication supply but access to our clinical team for ongoing support and guidance. We maintain transparent pricing without hidden fees, whilst discount codes FIRST40 and DOSE25 provide additional value for new and returning customers respectively. This holistic approach ensures your monthly investment delivers both clinical efficacy and professional support for sustainable weight management outcomes alongside a reduced-calorie diet and increased physical activity.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
